Cargando…

Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia

BACKGROUND: Trimethoprim/sufamethoxazole (TMP/SMX) is the recommended treatment for Pneumocystis jirovecii pneumonia (PCP). However, the efficacy and the safety of alternative salvage treatments are less guarauteed especially when patient experiences treatment failure and/or an adverse drug reaction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Tark, Sung, Heungsup, Chong, Yong Pil, Kim, Sung-Han, Choo, Eun Ju, Choi, Sang-Ho, Kim, Tae Hyong, Woo, Jun Hee, Kim, Yang Soo, Lee, Sang-Oh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031595/ https://www.ncbi.nlm.nih.gov/pubmed/29968978 http://dx.doi.org/10.3947/ic.2018.50.2.110

Ejemplares similares

Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
por: Kim, Tark, et al.
Publicado: (2018)

A Case of Pneumonia Caused by Pneumocystis jirovecii Resistant to Trimethoprim-Sulfamethoxazole
por: Lee, Sang Min, et al.
Publicado: (2015)

Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
por: Lee, Chang-Hoon
Publicado: (2018)

Prognostic implication of bronchoalveolar lavage fluid analysis in patients with Pneumocystis jirovecii pneumonia without human immunodeficiency virus infection
por: Chung, Chiwook, et al.
Publicado: (2022)

401. Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients After a 6-Month Trimethoprim–Sulfamethoxazole Prophylaxis: A Case–Control Study
por: Park, Se Yoon, et al.
Publicado: (2018)

Lifelong Prophylaxis With Trimethoprim-Sulfamethoxazole for Prevention of Outbreak of Pneumocystis jirovecii Pneumonia in Kidney Transplant Recipients
por: Goto, Norihiko, et al.
Publicado: (2017)

Clinical characteristics of hospital-onset Pneumocystis pneumonia and genotypes of Pneumocystis jirovecii in a single tertiary centre in Korea
por: Kim, Tark, et al.
Publicado: (2015)

Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation
por: Prasad, G. V. Ramesh, et al.
Publicado: (2019)

Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jirovecii Pneumonia in Deceased Donor Kidney Recipients
por: Ji, Jianlei, et al.
Publicado: (2021)

Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review
por: Haseeb, Abdul, et al.
Publicado: (2022)

Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies
por: Hammarström, Helena, et al.
Publicado: (2022)

Impact of an Intravenous Trimethoprim/Sulfamethoxazole Shortage on Treatment Outcomes Among HIV-Infected Patients with Pneumocystis jirovecii Pneumonia
por: Dilworth, Thomas J., et al.
Publicado: (2014)

Comparison of different microbiological procedures for the diagnosis of Pneumocystis jirovecii pneumonia on bronchoalveolar-lavage fluid
por: Franconi, Iacopo, et al.
Publicado: (2022)

Assessment of cytomegalovirus and cell-mediated immunity for predicting outcomes in non-HIV-infected patients with Pneumocystis jirovecii pneumonia
por: Kim, Taeeun, et al.
Publicado: (2017)

Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin
por: Wu, Huan-Huan, et al.
Publicado: (2022)

Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality
por: Song, Siyang, et al.
Publicado: (2022)

Molecular diagnosis and genotyping of Pneumocystis jirovecii in bronchoalveolar lavage samples obtained from patients with pulmonary disorder
por: Fata, Abdolmajid, et al.
Publicado: (2019)

Diagnostic Performance of Bronchoalveolar Lavage (1,3)-β-d-Glucan Assay for Pneumocystis jirovecii Pneumonia
por: Zhou, Shiwei, et al.
Publicado: (2020)

Multicenter Study of Trimethoprim/Sulfamethoxazole-Related Hepatotoxicity: Incidence and Associated Factors among HIV-Infected Patients Treated for Pneumocystis jirovecii Pneumonia
por: Yang, Jen-Jia, et al.
Publicado: (2014)

807. Trimethoprim/Sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis in B-cell lymphoma: A multicenter randomized double-blinded placebo-controlled trial
por: Angsutararux, Taksaon, et al.
Publicado: (2023)

Pneumocystis jirovecii Colonization in Non-HIV-Infected Patients Based on Nested-PCR Detection in Bronchoalveolar Lavage Samples
por: KHODADADI, Hossein, et al.
Publicado: (2013)

754. Performance Characterization of a Real Time PCR Assay for Pneumocystis jirovecii in Bronchoalveolar Lavage Fluid and Sputum
por: Bell, Drew T, et al.
Publicado: (2020)

Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
por: Koshy, Robin, et al.
Publicado: (2019)

Diagnostic performance of the (1–3)-β-D-glucan assay in patients with Pneumocystis jirovecii compared with those with candidiasis, aspergillosis, mucormycosis, and tuberculosis, and healthy volunteers
por: Son, Hyo-Ju, et al.
Publicado: (2017)

Evaluation of PCR in Bronchoalveolar Lavage Fluid for Diagnosis of Pneumocystis jirovecii Pneumonia: A Bivariate Meta-Analysis and Systematic Review
por: Fan, Li-Chao, et al.
Publicado: (2013)

Pneumocystis jirovecii pneumonia in a patient with HIV infection: complex diagnosis using Giemsa-stained bronchoalveolar lavage fluid
por: dos Santos, Louisy Sanches, et al.
Publicado: (2021)

Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial
por: Sohani, Zahra N., et al.
Publicado: (2022)

Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
por: Chapman, Fiona A., et al.
Publicado: (2019)

De Novo Assembly of the Pneumocystis jirovecii Genome from a Single Bronchoalveolar Lavage Fluid Specimen from a Patient
por: Cissé, Ousmane H., et al.
Publicado: (2012)

A New PCR-Based Assay for Testing Bronchoalveolar Lavage Fluid Samples from Patients with Suspected Pneumocystis jirovecii Pneumonia
por: Liotti, Flora Marzia, et al.
Publicado: (2021)

Diagnostic Value of Bronchoalveolar Lavage Fluid Metagenomic Next-Generation Sequencing in Pneumocystis jirovecii Pneumonia in Non-HIV Immunosuppressed Patients
por: Sun, He, et al.
Publicado: (2022)

Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids
por: Park, Jun Won, et al.
Publicado: (2018)

The cytological diagnosis of Pneumocystis jiroveci pneumonia in bronchoalveolar lavage
por: Kapatia, Gargi, et al.
Publicado: (2023)

The sul1 Gene in Stenotrophomonas maltophilia With High-Level Resistance to Trimethoprim/Sulfamethoxazole
por: Chung, Hae-Sun, et al.
Publicado: (2015)

Rothia mucilaginosa Pneumonia Diagnosed by Quantitative Cultures and Intracellular Organisms of Bronchoalveolar Lavage in a Lymphoma Patient
por: Cho, Eun-Jung, et al.
Publicado: (2013)

Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice
por: Lobo, Maria Luísa, et al.
Publicado: (2013)

Evaluation of the performance of DiaSorin molecular Pneumocystis jirovecii-CMV multiplex real-time PCR assay from bronchoalveolar lavage samples
por: Kilic, A., et al.
Publicado: (2020)

Quick versus Quantitative: Evaluation of Two Commercial Real-Time PCR Assays for the Detection of Pneumocystis jirovecii from Bronchoalveolar Lavage Fluids
por: Belanger, Corrie R., et al.
Publicado: (2023)

Usefulness of Cellular Analysis of Bronchoalveolar Lavage Fluid for Predicting the Etiology of Pneumonia in Critically Ill Patients
por: Choi, Sang-Ho, et al.
Publicado: (2014)

Sulfamethoxazole-Trimethoprim and Hyperkalemia in an Infant
por: Hudzik, Samantha A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qs1es9p2ml9l12jah0ccfbt4p5